secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001370053-25-000091
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued
------------------------------------------------------------------

- Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.
- Clinical remission 7% for both doses vs 5% and 4% endoscopic remission; placebo rates within historical ranges.
- Trial discontinued saving at least $10M; update on rosnilimab in RA expected H1 2026 via strategic capital.
- Reaffirms 2026 separation of biopharma from royalty assets; Jemperli royalties >$390M/yr at peak sales >$2.7B.
- Expects ~$300M cash end-2025 including $75M milestone from GSK for Jemperli reaching $1B global net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000091/0001370053-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000091/anab-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer